McKesson Corporation (MCK) faced a volatile week, with institutional investors losing 11% but noting long-term gains. The health conglomerate was applauded for outperforming competitors. The sale of Rexall and Well.ca to Birch Hill Equity Partners made headlines as did the unexpected underperformance in Q2 causing a decrease in MCK shares. Despite this, MCK continues to garner investor attention. News of Williams Financial LLC, and Meeder Advisory Services Inc. acquiring significant numbers of MCK shares instilled confidence. Despite a dip in earnings, strong revenue growth has led to raised full-year guidance. Even as MCK missed quarterly revenue, or rather because of it, it emerged as a strong momentum stock. McKesson's acquisition of a stake in a Florida Cancer Chain for $2.49 billion was also noted. Encouragingly, MCK also reported a 15% raise in its quarterly dividend. Despite some hiccups, Wall Street analysts see MCK as a buy, offering further credibility to its positive value proposition.
Mckesson Corporation MCK News Analytics from Thu, 04 Jan 2024 08:00:00 GMT to Sun, 15 Sep 2024 10:34:24 GMT -
Rating 5
- Innovation 3
- Information 7
- Rumor -5
